This study adds impetus to investigate the effects of RM with other anticancer drugs—cytotoxic agents, targeted, or immunotherapies, not only in ER+ but also in other subtypes of breast cancer and other solid tumors. The gene discussed is ESR1; the disease is breast cancer.